Navigation Links
Veridex Announces Agreement to Acquire the Assets of Immunicon Corporation
Date:6/11/2008

RARITAN, N.J., June 11 /PRNewswire-FirstCall/ -- Veridex, LLC announced today that it has signed an asset purchase agreement to acquire substantially all of the assets of Immunicon Corporation (OTC Bulletin Board: IMMC) for $31 million in cash subject to certain closing date adjustments, plus the discharge and release of certain claims owing to Veridex, LLC and the assumption of certain specified liabilities.

The assets to be acquired include intellectual property, product inventory and clinical data as well as all technologies related to the CellSearch(TM) System, the first diagnostic test to automate the detection and enumeration of circulating tumor cells (CTCs), cancer cells that detach from solid tumors and enter the blood stream. The CellSearch(TM) System is currently cleared for the prognosis and monitoring of patients with metastatic breast, metastatic colorectal and metastatic prostate cancer.

"This agreement represents a strategic opportunity for Veridex to continue to bring innovative diagnostic tests to the patients, physicians and laboratories involved in the fight against cancer," said Ken Berlin, General Manager, Veridex, LLC.

Veridex and Immunicon have partnered since 2000 to develop and commercialize novel cancer diagnostic platforms and products.

The transaction is subject to the approval by the bankruptcy court overseeing Immunicon's bankruptcy case. It is not expected to require anti-trust review or shareholder approval.

About Veridex

Veridex, LLC, a Johnson & Johnson company, is an organization dedicated to providing physicians with high-value in vitro diagnostic oncology products. Veridex is focused on developing products that will significantly benefit patients through earlier disease detection, and enable personalized medicine strategies to improve patient management and outcomes. The company develops cancer diagnostic products that may enable earlier disease detection as well as more accurate
'/>"/>

SOURCE Veridex, LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioSpecifics Technologies Corp. Announces Additional Sales of Stock in Private Placement Offering
2. Diffusion Pharmaceuticals Announces Addition of Mark T. Giles to its Board of Directors
3. Oncolytics Biotech Inc. Announces Start of Enrolment in Phase 1/2 Ovarian Cancer Clinical Trial with REOLYSIN(R)
4. Appature Announces onKey as an Innovative Platform for Creating Microsoft HealthVault-Compatible Applications
5. Premier Research Announces Completion of Management Buyout
6. ProMetic announces Octapharma publication of PRDTS prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China
7. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
8. onTargetjobs Announces Appointment of Michael Tansey as New CEO
9. Tethys Bioscience Announces Expanded Availability of PreDx(TM) Diabetes Risk Test
10. QLT announces positive Health Canada decision on Aczone(R)
11. ETHICON, INC. Announces Revised Label For REGRANEX(R) (becaplermin) Gel 0.01%
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... LOS ANGELES , Aug. 4, 2015   ... announced the recent acquisition of LifeLine Cryogenics, an east ... the New York tristate area. ... tissues, and all prepaid contracts will be honored. ... of cryogenics services, offering storage of sperm, eggs, embryos, ...
(Date:8/3/2015)... , Aug. 3, 2015  MiMedx Group, Inc. ... utilizing human amniotic tissue and patent-protected processes to develop ... Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental ... at the 35 th Annual Canaccord|Genuity Growth Conference ... "Pete" Petit, Chairman and CEO, William C. Taylor ...
(Date:8/3/2015)... , August 3, 2015 ... the commercialization of its Bio-electrical Signal Therapy device ("BST ... treatment of hard to heal chronic wounds, today announced ... with Chemipal, an Israeli distributor specializing in medical devices, ... Chemipal is a 70 years old, sales, ...
(Date:7/31/2015)... In today,s fast changing healthcare environment, ... positive health outcomes, improve profitability and enhance their ... in their communities. At ThoughtSpot 2015, Good ... announced a new set of innovative capabilities that ... help independent pharmacies endure the industry,s most pressing ...
Breaking Biology Technology:FamilyCord Announces Acquisition of LifeLine Cryogenics 2MiMedx To Present At 35th Annual Canaccord|Genuity Growth Conference 2E-QURE Corp Signs Second Distribution Agreement in Israel 2E-QURE Corp Signs Second Distribution Agreement in Israel 3AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3
... Osteotech, Inc. (Nasdaq: OSTE ), a leader ... today that the Company,s second quarter ended June 30, 2010 ... Monday, August 9, 2010 .  The management team of Osteotech ... 9, 2010 , at 9:00 a.m. (EDT) to discuss ...
... Mass. , Aug. 4 New England ... Michael Smith Genome Sciences Center has selected New England ... sequencing library construction reagents. NEBNext DNA Sample Prep Reagent ... and validated for sample preparation for next generation sequencing, ...
... Elusys Therapeutics, Inc. (Elusys), a privately-held ... second contract year of funding valued at $40.6 million ... and treatment of anthrax infection following a biowarfare attack. This ... received under this contract and is part of a potential ...
Cached Biology Technology:Osteotech Announces Second Quarter 2010 Financial Results Release and Conference Call 2Canada's Michael Smith Genome Sciences Center Validates NEBNext™ DNA Sample Preparation Reagents From New England Biolabs for Use in Next Generation Sequencing 2Canada's Michael Smith Genome Sciences Center Validates NEBNext™ DNA Sample Preparation Reagents From New England Biolabs for Use in Next Generation Sequencing 3Elusys Awarded Additional $40.6 Million Under Existing U.S. Government Contract to Fund Advanced Development of Anthim, a New Treatment for Anthrax 2Elusys Awarded Additional $40.6 Million Under Existing U.S. Government Contract to Fund Advanced Development of Anthim, a New Treatment for Anthrax 3
(Date:7/31/2015)... Den 10. internationale konference om Genomik (ICG-10, ... - 25. oktober i Shenzhen , ... i år. Siden starten i 2006 er ICB blevet ... og er en af de mest dynamiske, entusiastiske og ... nylige gennembrud og fremskridt inden for ,omik,-forskning, som yderligere ...
(Date:7/31/2015)... 31 de julho de 2015 A 10 ... ) será realizada pela BGI de 22-25 de outubro de ... A conferência está celebrando seu 10 o. ... ICG se tornou uma das reuniões mais influentes do ... científicos mais dinâmicos, entusiastas e prazerosos. ...
(Date:7/31/2015)... SHENZHEN, China , 31 de julio de 2015 /PRNewswire/ ... www.icg-10.org ) se celebrará por medio de BGI del 22 ... China . Este año, la conferencia ... 2006, ICG se ha convertido en una de las reuniones ... de ser una de las reuniones más dinámicas, entusiastas y ...
Breaking Biology News(10 mins):Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3
... Vermillion, Inc. (NASDAQ: VRML ), a ... health, announced the signing of a cooperative research and development ... Materiel Command (USAMRMC). The agreement kicks off ... Treatment Algorithm for Adnexal Masses in Women," and follows ...
... is pleased to announce it has received a grant ... Advanced Life Sciences Training Program. The grant will ... July 2013 for all five classes of participants in ... 2008. The Fellows Program is a high-level life science ...
... KISS 1 is a metastasis-suppressor gene which helps to ... ovarian cancers to name a few. But new ... Dentistry shows that kisspeptins peptide products of KISS1, actually ... grade and metastatic potential. The research is published ...
Cached Biology News:U.S. Army and Vermillion to Assess Health and Economic Benefits of OVA1 as a Standard of Care 2U.S. Army and Vermillion to Assess Health and Economic Benefits of OVA1 as a Standard of Care 3U.S. Army and Vermillion to Assess Health and Economic Benefits of OVA1 as a Standard of Care 4Keystone Symposia announces grant from Alfred P. Sloan Foundation 2
Formula variant: With the macro- and micronutrients as described by Lloyd and McCown (1981). Preparation Quantity Equivalency: Formulated to contain 2.3 grams of powder per liter of medium. Physical ...
... separation and fractionation of nucleic-acid ... nuclei from cytosolic proteins A ... greatly facilitating study of low-abundance ... acid binding proteins (e.g., transcription ...
... whose sequence corresponds to residues 1-18 from rat rab 3D. ... - A - S - A - S - E - ... - D - A - A - D - Q - ... control experiments with the polyclonal antibody that reacts with this product ...
... or individual RNA sequences from high throughput synthesis ... RNAs from LC Sciences. These products provide a ... of DESIGNED sequences delivered in a microtube as ... a single verified RNA sequence. This is a ...
Biology Products: